The challenges of the use of NOACs incancer patients with AF and current expert opinion on this subject have been summarized in this review article. (Anatol J Cardiol 2020; 23: 10-8)
📌 3 Key Takeaways
🎯
Objective & Hypothesis:To the best of our knowledge, non-vitamin K antagonist oral anticoagulants (NOACs), or direct oral anticoagulants, have not been tested in randomized trials conducted in patients with atrial fibrillation (AF), affected by malignant disease.
📊
Key Findings & Data:However, their use in patients with cancer is increasing,while real-life evidence for their effectiveness and safety in this vulnerable subset of patients is growing.
💡
Conclusion & Impact:The challenges of the use of NOACs incancer patients with AF and current expert opinion on this subject have been summarized in this review article. (Anatol J Cardiol 2020; 23: 10-8)
🔬Design:Review & Systematic Survey
📍Scope:2020 Verileri
⚙️Variables:Domain Parameters
Özet
To the best of our knowledge, non-vitamin K antagonist oral anticoagulants (NOACs), or direct oral anticoagulants, have not been tested in randomized trials conducted in patients with atrial fibrillation (AF), affected by malignant disease. However, their use in patients with cancer is increasing,while real-life evidence for their effectiveness and safety in this vulnerable subset of patients is growing. The challenges of the use of NOACs incancer patients with AF and current expert opinion on this subject have been summarized in this review article. (Anatol J Cardiol 2020; 23: 10-8)
🔖
Cite This Article
UNDAS, A., DRABIK, L. (2020). Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation. The Anatolian Journal of Cardiology, Cilt: 23 - Sayı: 1, 10–18. https://ajindex.com/articles/365174
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of neworal anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet 2014; 383: 955–62
Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39: 1330–93
Fitzpatrick T, Carrier M, Le Gal G. Cancer, atrial fibrillation, and stroke. Thromb Res 2017; 155: 101–5
Gorczyca I, Wożakowska-Kapłon B, Starzyk K, Szpotowicz A, Stec A. Evaluation of the recommended prevention of thrombosis in hospitalised patients with atrial fibrillation and high thromboembolism risk. Kardiol Pol 2018; 76: 625–32
Grześk G, Janiszewska E, Malinowski B, Kubica A, Wiciński M. Adherence in patients with atrial fibrillation treated with dabigatran. Kardiol Pol 2018; 76: 1562-3
Sayın B, Okutucu S, Yılmaz MB, Özdemir K, Aydınlar A, Şahin DY, et al. Antithrombotic treatment patterns and stroke prevention in patients with atrial fibrillation in TURKEY: inferences from GARFIELDAF registry. Anatol J Cardiol 2019; 21: 272–80
Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Kardiol Pol 2018; 76: 1283-98
Sawicka-Powierza J, Buczkowski K, Chlabicz S, Gugnowski Z, Powierza K, Ołtarzewska AM. Quality control of oral anticoagulation with Vitamin K antagonists in primary care patients in Poland: A multicentre study. Kardiol Pol 2018; 76: 764–9
Cavallari I, Patti G. Efficacy and safety of oral anticoagulation in elderly patients with atrial fibrillation. Anatol J Cardiol 2018; 19: 67-71
Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al.; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893-962
Mery B, Guichard JB, Guy JB, Vallard A, Barthelemy JC, Da Costa A, et al. Atrial fibrillation in cancer patients: Hindsight, insight and foresight. Int J Cardiol 2017; 240: 196–202
Sorigue M. On cancer and atrial fibrillation: Nuances and limitations. Eur J Intern Med 2019; 62: e2